Long-Term Outcomes After Thoracoscopic Resection of Stage I and II Thymoma: A Propensity-Matched Study

Chao, Yin‐Kai; Liu, Yun-Hen; Hsieh, Ming‐Ju; Wu, Yi‐Cheng; Chen, Tzu-Ping; Lu, Ming‐Shian; Lu, Hung-I; Liu, Huiping

doi:10.1245/s10434-014-4068-9

Cited by 31 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intra operative blood loss in present study was 45±30 ml ,this was in either similar or less when compared to the studies published in the literature. [7][8][9][10] There is sufficient evidence that intra operative blood loss is less in VATS Thymectomy compared to open thymectomy, this fact is supported by findings in our study. Mean operating time in our study was 104 mins with a range of 78 to 145 mins.…”

Section: Discussionsupporting

confidence: 89%

Safety and feasibility of video assisted thoracoscopic thymectomy for myasthenia gravis: a single centre experience

et al. 2019

View full text Add to dashboard Cite

Background: Myasthenia gravis (MG) is an autoimmune disease affecting acetylcholine postsynaptic receptor of voluntary muscles. Thymectomy is a mainstay in the treatment for myasthenia gravis with or without thymoma. For many years transsternal and transcervical thymectomy had been the most common approaches used, video assisted thoracoscopic thymectomy is still not accepted as approach of choice. We intend to study the role of Video assisted thoracoscopic thymectomy for myasthenia gravis in central Indian population. Methods: Study was conducted in single tertiary care institute from January 2015 to November 2018. It is a prospective study. Aims of the study were to evaluate the safety and feasibility of video assisted thoracoscopic thymectomy for patients of myasthenia gravis. All patients of myasthenia gravis who underwent underwent video assisted thoracoscopic thymectomy (VATS) were included in the study. Intraoperative and postoperative details were studied to assess the safety and feasibility of VATS for treatment of myasthenia gravis. Results: 16 patients including 7 men and 9 women with the mean age of 35.5 years were investigated. All patients had myasthenia gravis, 12 pts had thymoma while remaining 4 pts had normal thymus. Mean operating time was 104 mins, Mean intraoperative blood loss was 45 ml (range 20 to 60 ml). There was no major intraoperative or postoperative complication or mortality. Mean ICU stay and hospital stay was 33 hrs and 4.25 days respectively. Conclusions: VATS thymectomy is safe and effective approach for the treatment of MG with or without thymoma. MG treated by VATS resulted in comparable neurological outcomes to those associated with the transsternal approach.

show abstract

Section: Discussionsupporting

confidence: 89%

Safety and feasibility of video assisted thoracoscopic thymectomy for myasthenia gravis: a single centre experience

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In agreement with previous reports (12,38,39), several authors demonstrated the decreased invasiveness of TT for thymoma. Most of the reports in this review revealed that TT showed a significantly shorter post-operative hospital stay, decreased intraoperative blood loss, and fewer complications compared to OT ( Table 2).…”

Section: Surgical Treatmentsupporting

confidence: 93%

Surgical and oncological outcomes of thoracoscopic thymectomy for thymoma

Odaka¹,

Tsukamoto²,

Shibasaki³

et al. 2017

J. Vis. Surg.

View full text Add to dashboard Cite

type classification are valuable predictors of the prognosis of thymoma; hence, the optimal treatment for thymoma should be performed according to these two. TT is less invasive, with equivalent oncological outcomes, when compared with the OT. Minimally invasive surgery including TT for stage I-II thymomas is becoming the mainstay of therapy. (16,(20)(21)(22)(23). In our previous study (24), Masaoka stage III-IV thymoma patients experienced more recurrences than those with stage I-II patients. The 5-year disease-free survival (DFS) for stage III-IV thymomas was significantly poorer than those for stage I and II thymoma (47% vs. 97.5% and 94.1%, respectively). Hence, the Masaoka stage was a valuable predictor of the prognosis of thymoma. Keywords Pathologic classificationThe pathologic classification of thymoma has remained controversial for many years (25). The World Health Organization (WHO) has developed the most widely adopted pathologic classification for epithelial tumor of thymus by taking into consideration both histological and morphological features (26). There are two staging systems for epithelial tumor of thymus (27). Most widely used clinical stage was first described by Masaoka et al. in 1981, and it is a clinical staging system describing thymomas in terms of local extension or invasion of the tumor (6). The TNM staging follows the pattern of T for tumor descriptor, N for nodal spread, and M for distance metastasis. In 1999, the WHO Consensus Committee published a histologic typing system for neoplasms of the thymus (28). Thymomas are classified into types A, AB, B1, B2, B3, and C based on the morphology of epithelial cells and ratio of lymphocyteto-epithelial cells. Recently, the WHO Consensus Committee recommended that epithelial tumors of thymus be classified as thymoma, including type A, AB, B1, B2, and B3 thymoma and thymic carcinoma (29). Most of the WHO type A, AB, B1, and B2 thymomas are benign; however, types B3 and C have malignant potential (30). Our study (24) demonstrated that 16 of 140 thymomas patients experienced recurrences. Of those 16 patients, 12 patients had WHO type B3 or C thymomas. Thus, pathological aggressiveness seems to strongly influence recurrence. Several reports have indicated the impact of the WHO type on the decisionmaking during clinical treatments (26). Surgical treatmentMost patients having Masaoka stage I-II thymoma receive surgical treatment. Recently, TT has been attempted as a surgical treatment for thymoma. TT for thymoma consists of extended thymectomy (ET), total thymectomy, subtotal thymectomy (STT), and partial thymectomy according to the classification of the extent of the thymus resected. In this review, a few authors classified thymectomy by total and partial thymectomy, while some authors do not describe the resected extent of thymus clearly. Total thymectomy was defined as the resection of the entire thymus, and ET was defined as the resection with the thymus and surrounding fat tissues together. ET was usually performed in patients who had MG. F...

show abstract

“…With regard to the surgical treatment of thymoma, the preferred surgical approach and procedure remain controversial. According to previous reports [5,6], several authors have endorsed less invasive thoracoscopic surgery procedures for thymoma. Pennathur et al [7] reported their surgical results from a comparative study of video-assisted thoracoscopic surgery versus OT for patients with early-stage thymoma.…”

Section: Long-term Survivalmentioning

confidence: 99%

Comparison of oncological results for early- and advanced-stage thymomas: thoracoscopic thymectomy versus open thymectomy

et al. 2016

View full text Add to dashboard Cite

show abstract

Long-Term Outcomes After Thoracoscopic Resection of Stage I and II Thymoma: A Propensity-Matched Study

Abstract: VATS appears feasible for patients with stage I and II thymoma and is associated with better perioperative outcomes than MST. The oncological outcomes are also similar.

Cited by 31 publications

References 21 publications

Safety and feasibility of video assisted thoracoscopic thymectomy for myasthenia gravis: a single centre experience

Safety and feasibility of video assisted thoracoscopic thymectomy for myasthenia gravis: a single centre experience

Surgical and oncological outcomes of thoracoscopic thymectomy for thymoma

Comparison of oncological results for early- and advanced-stage thymomas: thoracoscopic thymectomy versus open thymectomy

Contact Info

Product

Resources

About